Press news Biocartis Group NV: Results of the Extraordinary Shareholders’ Meeting held on 25 September 2020


You May Also Like

New Pancreatic Ductal Adenocarcinoma Research Published in Journal of Visualized Experiments

Paper describes well-established protocols for PDAC orthotopic tumor homograft model development and immunoprofiling SAN ...

Leap Therapeutics Announces Pricing of $14 Million Public Offering of Common Stock

CAMBRIDGE, Mass., March 23, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology ...